Antibody-IL2 Fusion Protein Delivery by Gene Transfer
Annual rept. 1 Oct 97-30 Sep 98
Pagination or Media Count:
Our team has pursued preclinical and clinical investigations combining the administration of IL-2 with tumor reactive monoclonal antibodies. Preclinical models, developed by our collaborators R.Reisfeld and S.Gillies, have shown the antitumor efficacy of antibody-IL2 fusion proteins in murine models. The KS-IL2 fusion protein recognizes the KSA antigen expressed on a broad range of human carcinomas, including breast cancer and is effective at preventing outgrowth of the KSA positive, syngeneic CT26-KSA carcinoma cell line in mice. The experiments now underway in this research study are designed to help improve the future clinical efficacy of the KS-IL2 reagent by clarifying its actions, testing its efficacy in murine models simulating pitfalls with human immunotherapy, and translating these results to human application through in vitro studies.
- Genetic Engineering and Molecular Biology
- Medicine and Medical Research